SEC Form 4 · accession 0001140361-16-056681
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Pendarvis
Officer — Chief Administrative Officer
Period of report
Mar 3, 2016
Accepted (ET)
Mar 7, 2016 · 3:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Mar 3, 2016 | M | 6,000 | $33.70 | A | 80,287 | D | |
| ResMed Common StockF3 | Mar 3, 2016 | S | 6,000 | $57.26 | D | 74,287 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF2 | $33.70 | Mar 3, 2016 | M | 6,000 | D | Nov 11, 2011 | Nov 11, 2017 | ResMed Common Stock | 6,000 | 48,033 | D |
Explanation of responses
- F1The transaction was conducted under a 10b5-1 Plan as defined under the Securities Exchange Act of 1934, as amended.
- F2Represents date options first became exercisable. Options vest 1/4 per year on the anniversary of the grant.
- F3This transaction was executed in multiple trades at prices ranging from $57.01 to $57.52. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.